Future challenges for health economics and health technology assessment of biological drugs.

摘要

In this paper, some present and future challenges of health economics and health technology assessment (HTA) of biological drugs are discussed in general with particular emphasis of their utilization in rheumatology. The development and challenges of HTA in the new European Union member states are briefly touched to evaluate how their HTA agencies are coping with the increased demand of the funders and policy makers. The most important question is whether more methodological development is needed or more local data should be required (and what kind) or more international collaboration is the solution or do we need both at the same time?